Us Bancorp \De\ Nurix Therapeutics, Inc. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

A detailed history of Us Bancorp \De\ transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 582 shares of NRIX stock, worth $12,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares

582

Previous 1,232 52.76%

Holding current value

$12,355

Previous $25,000 48.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	SELL	$18.93 - $25.69 $12,304 - $16,698	-650 Reduced 52.76%	582 $13,000
Q2 2024 Aug 06, 2024	BUY	$12.02 - $21.3 $11,154 - $19,766	928 Added 305.26%	1,232 $25,000
Q1 2024 May 07, 2024	BUY	$7.77 - $15.66 $1,787 - $3,601	230 Added 310.81%	304 $4,000
Q4 2023 Feb 09, 2024	SELL	$4.25 - $10.71 $480 - $1,210	-113 Reduced 60.43%	74 $0
Q3 2023 Nov 03, 2023	SELL	$7.86 - $10.08 $5,030 - $6,451	-640 Reduced 77.39%	187 $1,000
Q2 2023 Aug 09, 2023	BUY	$8.7 - $13.28 $69 - $106	8 Added 0.98%	827 $8,000
Q1 2023 May 09, 2023	BUY	$8.56 - $13.26 $6,128 - $9,494	716 Added 695.15%	819 $7,000
Q4 2022 Feb 13, 2023	SELL	$9.86 - $14.59 $1,636 - $2,421	-166 Reduced 61.71%	103 $1,000
Q3 2022 Oct 27, 2022	BUY	$12.33 - $19.81 $2,404 - $3,862	195 Added 263.51%	269 $4,000
Q1 2022 May 11, 2022	SELL	$12.94 - $29.65 $672 - $1,541	-52 Reduced 41.27%	74 $1,000
Q4 2021 Feb 11, 2022	BUY	$26.43 - $34.5 $1,955 - $2,553	74 Added 142.31%	126 $4,000
Q3 2021 Nov 10, 2021	SELL	$22.71 - $36.69 $2,475 - $3,999	-109 Reduced 67.7%	52 $2,000
Q2 2021 Aug 05, 2021	BUY	$24.21 - $35.89 $3,704 - $5,491	153 Added 1912.5%	161 $4,000
Q1 2021 Apr 28, 2021	BUY	$26.98 - $50.17 $215 - $401	8 New	8 $0

Others Institutions Holding NRIX

# of Institutions

181

Shares Held

68.1M

Call Options Held

78K

Put Options Held

53.8K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account